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Abstract: Three factor Xa inhibitors have been studied in the treatment of venous
thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events.
Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials
for this indication when compared to current standard of therapy with similar or less bleeding.
Nevertheless, the agents all offer different pharmacological profiles, which have an impact on
patient selection and potential advantages in clinical practice.
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Introduction
Anticoagulant therapy is the cornerstone of venous thromboembolism (VTE) treatment, and is typically provided with an initial parenteral agent, overlapping to an
oral agent for maintenance therapy and prevention of recurrent VTE events. Patients
are often treated with anticoagulant therapy for 3–6 months depending on the initiating event and other clinical factors; however, treatment may be extended longer
to prevent recurrent VTE events.1 There has been little change to this fundamental
approach to treating acute VTE until the recent introduction of the new, targetspecific oral anticoagulants: direct thrombin inhibitors and factor Xa inhibitors.
Three oral factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have all been
studied in Phase III clinical trials for the treatment of VTE and are US Food and
Drug Administration approved for this indication. The Xa inhibitors offer several
advantages over traditional therapy with parenteral anticoagulant bridging to a
vitamin K antagonist. This review will highlight the pharmacology of the oral Xa
inhibitors, the available clinical trial data, and the potential advantages and role for
their use in VTE treatment.

Pharmacology of factor Xa inhibitors
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Factor Xa inhibitors are small molecules that selectively and reversibly bind to the
active site of activated factor X (Xa), which blocks the interaction with its substrate
in a rapid and competitive fashion, therefore inhibiting the final effects of thrombin
generation.2 They inhibit both free factor Xa in solution and within a clot, and have no
direct effect on platelet aggregation. Inhibiting the coagulation cascade in a targeted
fashion has several advantages. Targeting factor Xa, where the intrinsic and extrinsic
pathways meet, inhibits thrombin generation from both pathways. In comparison
to directly blocking thrombin, it is theorized that by inhibiting thrombin generation
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more proximally at factor Xa, the amplification of thrombin
generation that occurs downstream may be prevented and
therefore may require less drug for inhibition compared to
the amount needed to directly inhibit at thrombin.2,3 Unlike
thrombin, factor Xa also has minimal functions outside of
the role of coagulation; therefore, negative effects as a consequence of inhibition may be limited.4,5
The Xa inhibitors exhibit linear pharmacokinetics and
display predictable anticoagulant responses, thereby avoiding the need for routine monitoring.2 In general, all three of
the oral factor-Xa inhibitors are rapidly absorbed, reaching a
maximum concentration within approximately 3 hours (see
Table 1).2–9 Minor differences in pharmacokinetics exist;
for example, rivaroxaban has a high bioavailability which
is dose dependent. The doses utilized for VTE treatment
(15–20 mg) must be administered with food to maintain
the high bioavailability, area under the curve (AUC), and
maximum peak concentration (Cmax).5 Once in the plasma,
rivaroxaban is highly protein-bound and has a low volume
of distribution (Table 1), whereas apixaban and edoxaban’s
exposure and peak concentration are not affected by a fed
state and therefore can be administered with or without
food.7,10–12
Apixaban has a small volume of distribution, suggesting that it is primarily distributed in the blood and is
87% protein bound.2,7 In comparison, edoxaban has a high
volume of distribution due to its relatively low protein
binding (Table 1).2,13,14 Since it is minimally protein-bound,
edoxaban may be able to be removed by dialysis.
All three agents are renally eliminated to varying degrees
and have an elimination half-life much less than the vitamin K

antagonists. Rivaroxaban has a dual mechanism of excretion,
with one-third of the absorbed dose excreted unchanged in
the urine and the remaining two-thirds of the dose excreted
as inactive metabolites in both the urine and feces.2,6,15 Its
short half-life of 5–9 hours is prolonged in elderly patients to
11–13 hours due to age-related renal-function decline.2,5,6 As
a patient’s renal function worsens, the clearance of rivaroxaban is reduced and the Cmax is increased.6 Therefore, use for
VTE treatment should be avoided in patients with severe renal
impairment (creatinine clearance [CrCl] ,30 mL/min) as these
patients were also excluded from the clinical trials.6,15 Apixaban
is minimally excreted by the kidneys – approximately 25%
– with the remainder excreted by the hepatobiliary route in
the feces. As renal function declines, exposure to apixaban
may increase and patients with a CrCl ,30 mL/min were
also excluded from clinical trials. Caution may be warranted
in this patient population; however, the medication is now
approved for use in patients with severe end-stage kidney
disease receiving hemodialysis.7 Edoxaban is eliminated via
multiple pathways with 35% eliminated in the urine, yet over
70% of the edoxaban dose is excreted unchanged.2,8,16
All three factor Xa inhibitors are partially metabolized through the CYP450 system to some extent and are
P-glycoprotein (P-gp) substrates, which carries implications
for potential drug interactions and will be discussed later in
this paper (Table 1).

Phase III clinical trials in acute VTE
treatment
All three factor Xa inhibitors have been studied for the acute
treatment of VTE, either as separate deep vein thrombosis

Table 1 Factor-Xa inhibitor’s pharmacokinetic and pharmacodynamic characteristics
Rivaroxaban

Apixaban

Edoxaban

VTE dose

15 mg BID ×3 weeks, then 20 mg once daily

10 mg BID ×7 days, then 5 mg BID

Renal dose adjustment

Yes, CrCl ,30 mL/min

Yes, CrCl ,25 mL/min or Scr .2.5

Tmax (h)
VD (L)
Half-life (h)
Bioavailability
Protein binding
Metabolism
Elimination
Effects of food
CYP3A4 substrate
P-gp substrate

2–4
50
5–9
.80%
92%–95%
CYP3A4, CYP2J2
33% renal
Cmax and AUC increased; take with food
Yes
Yes

3–4
∼23*
9–14
.50%
87%
CYP3A4
25% renal
Cmax and AUC unchanged
Yes
Yes

60 mg QD after 7–10 days
heparin
Assumed 50% reduction if
CrCl ,50 mL/min
1–2
.300
10–14
62%
40%–59%
CYP3A4
35% renal
Cmax and AUC unchanged
Yes
Yes

Notes: *VD =0.3 L/kg and assuming a 75 kg patient. The HOKUSAI-VTE trial20 reduced dose by 50% in those patients with a CrCl of 30 to 50 mL/min, or a body weight
60kg, or in patients receiving concomitant treatment with potent P-gp inhibitor.
Abbreviations: AUC, area under the curve; BID, twice daily; Cmax, maximum peak concentration; CrCl, creatinine clearance; CYP, cytochrome P450; h, hours; min,
minutes; P-gp, P-glycoprotein; QD, every day; Scr, serum creatine; Tmax, time to maximum concentration; VD, volume of distribution; VTE, venous thromboembolism.
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(DVT) and pulmonary embolism (PE) trials, or together. The
EINSTEIN investigators studied the use of rivaroxaban as
initial treatment for both acute DVT and PE.17,18 The Acute
DVT study was a randomized, open-label study comparing
rivaroxaban 15 mg twice daily (BID) for 3 weeks, then 20
mg daily, to standard therapy of enoxaparin bridged to a vitamin K antagonist in 3,429 patients with acute, symptomatic,
objectively confirmed proximal DVT.17 Randomization and
rivaroxaban treatment started on day 1 without a heparin
lead-in. It was an event driven, noninferiority study with 62%
of patients treated for 6 months. The primary efficacy outcome
was symptomatic recurrent VTE, which was experienced by
2.1% of patients in the rivaroxaban group compared to 3.0%
of patients receiving standard therapy (hazard ratio [HR] 0.68;
95% confidence interval [CI] 0.44–1.04; P,0.001 for noninferiority). There was no statistically significant difference in
the primary safety outcome of first major or clinically relevant
nonmajor bleed (Table 2). Patients in the standard therapy group
were on enoxaparin for a median of 8 days (interquartile range
6–11 days), then bridged to warfarin or acenocoumarol with
a goal International Normalized Ratio (INR) 2–3, and spent
57.7% of time in therapeutic range (TTR). Therefore, it was
determined that rivaroxaban was noninferior to standard therapy
for the treatment of acute DVT.
A similar study was conducted by the same investigators looking at treatment of acute PE.18 EINSTEIN PE was
a randomized, open-label study in 4,832 patients with acute
symptomatic PE with or without DVT randomized to rivaroxaban 15 mg BID for 3 weeks then 20 mg once daily, or

standard therapy of enoxaparin bridging to warfarin. Once
again, rivaroxaban was initiated without a heparin lead-in.
Twenty-five percent of patients had a concomitant DVT
and the majority of patients were treated for 6–12 months.
Rivaroxaban was found to be noninferior to standard therapy
in reducing the rate of recurrent VTE (2.1% versus 1.8%;
HR 1.12; 95% CI 0.75–1.68; P=0.003 for noninferiority)
with a similar rate of major or clinically relevant nonmajor
bleeding during treatment (10.3% versus 11.4%; HR 0.90;
95% CI 0.76–1.07; P=0.23), although major bleeding was
significantly reduced (1.1% versus 2.2%; HR 0.49; 95% CI
0.31–0.79; P=0.003). The TTR for patients on warfarin was
62.7% and the mean study duration was 9 months.
Apixaban has been studied for the treatment of acute VTE
in the AMPLIFY study: a randomized, double-blinded, noninferiority trial.19 A total of 5,395 patients with an acute DVT,
PE, or both were included and randomized to receive either
apixaban 10 mg BID for 7 days then 5 mg BID for 6 months
(without a heparin lead-in phase), or standard therapy with
enoxaparin bridging to warfarin, with a goal INR 2–3, for
6 months. The majority of patients (65%) had a DVT only
with 89.8% being unprovoked and 25% were treated for a PE
only. The incidence of recurrent symptomatic VTE or death
related to VTE, which was the primary efficacy outcome, was
met in 2.3% of those patients receiving apixaban compared
to 2.7% in the conventional group, meeting noninferiority
criteria (Table 2). Interestingly, major bleeding, the primary
safety outcome, was significantly less in the apixaban group
compared to the conventional group (0.6% versus 1.8%;

Table 2 Phase III clinical trial results for the treatment of acute venous thromboembolism
Phase III trials
Acute VTE treatment
 EINSTEIN-DVT17
 EINSTEIN-PE18
AMPLIFY19

HOKUSAI-VTE20
Extended VTE treatment
 EINSTEIN-Ext17
AMPLIFY-Ext21,*

Major outcomes

Oral Xa inhibitor
(% of events)

Standard therapy
(% of events)

Hazard ratio, 95% confidence
interval

Symptomatic recurrent VTE
1st M/CRNMB
Recurrent VTE
1st M/CRNMB
1st recurrent VTE or VTE-related
death
Major bleed
Symptomatic recurrent VTE
Clinically relevant bleeding

2.1%
8.1%
2.1%
10.3%
2.3%

3.0%
8.1%
1.8%
11.4%
2.7%

HR 0.68 (95% CI 0.44–1.04); P,0.001
HR 0.97 (95% CI 0.76–1.22); P=0.77
HR 1.12 (95% CI 0.75–1.68); P=0.003
HR 0.90 (95% CI 0.76–1.07); P=0.23
HR 0.84 (95% CI 0.6–1.8); P,0.001

0.6%
3.2%
8.5%

1.8%
3.5%
10.3%

HR 0.31 (95% CI 0.17–0.55); P,0.001
HR 0.89 (95% CI 0.70–1.13); P,0.001
HR 0.81 (95% CI 0.71–0.94); P=0.004

Symptomatic recurrent VTE
1st M/CRNMB
Recurrent VTE/death from any
cause
Major bleeding

1.3%
6.0%
4.2% (5 mg)
3.8% (2.5 mg)
0.1% (5 mg)
0.2% (2.5 mg)

7.1%
1.2% (placebo)
11.6% (placebo)

HR 0.18 (95% CI 0.09–0.39); P,0.001
HR 5.19 (95% CI 2.3–11.7); P,0.001
HR 0.36 (95% CI 0.25–0.53); P,0.001
HR 0.33 (95% CI 0.22–0.48); P,0.001
HR 0.25 (95% CI 0.03–2.24); NS
HR 0.49 (95% CI 0.09–2.64); NS

0.5% (placebo)

Notes: *This study included two doses of Xa inhibitor and only one placebo. Data from.17-20,21
Abbreviations: CI, confidence interval; HR, hazard ratio; M/CRNMB, major or clinically relevant nonmajor bleeding; VTE, venous thromboembolism; NS, not significant.
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HR 0.31; 95% CI 0.17–0.55; P,0.001). This trend was also
seen in the secondary endpoint of major bleeding or clinically
relevant nonmajor bleeding: occurring 4.3% in the apixaban
group versus 9.7% in conventional therapy, P,0.001. In the
conventional group, the median duration of the enoxaparin
bridge was 6.5 days (interquartile range 5–8 days) and the
TTR for warfarin was 61%. Efficacy and safety endpoint
results were found to be consistent in those study centers
where warfarin’s mean TTR exceeded 68%.
Edoxaban has been studied for the treatment of VTE in
a randomized, double-blinded trial: HOKUSAI-VTE.20 The
study required a heparin lead-in for the edoxaban arm (enoxaparin or unfractionated heparin) for at least 5 days followed
by edoxaban 60 mg once daily compared to a heparin bridge
over to therapeutic warfarin, INR 2–3, in patients with DVT,
PE, or both.20 Patients receiving edoxaban were given a reduced
dose of 30 mg once daily if they had a CrCl of 30–50 mL/min,
weighed 60 kg or less, or were receiving concomitant treatment with a potent P-gp inhibitor. Patients were evaluated after
12 months regardless of the duration of treatment the patient
received. About two-thirds of the overall 8,240 patients were
treated for a DVT only. Edoxaban was determined to be noninferior to warfarin in preventing the primary efficacy outcome:
incidence of symptomatic recurrent VTE (3.2% of edoxaban
versus 3.5% of warfarin patients; HR 0.89; 95% CI 0.70–1.13;
P,0.001) (Table 2). The primary safety outcome of clinically
relevant bleeding was found in 8.5% of patients receiving
edoxaban and 10.3% of those receiving warfarin (HR 0.81;
95% CI 0.71–0.94; P=0.004), meeting superiority criteria. This
decreased trend in bleeding was also observed amongst the
17% of patients who received the reduced 30 mg dose. Patients
receiving warfarin were in range 63.5% of time.

Phase III clinical trials in extended
VTE treatment
In addition to acute VTE treatment, rivaroxaban and apixaban were also studied as extended therapy to prevent further
recurrent events. The EINSTEIN investigators studied
rivaroxaban for the extended or continued treatment of
VTE in the EINSTEIN-Extension trial.17 This was an eventdriven, superiority, double-blinded study that investigated
1,188 patients with a confirmed symptomatic VTE who
had been treated for 6 or 12 months with rivaroxaban or a
vitamin K antagonist and then randomized to receive continued therapy with rivaroxaban 20 mg daily or placebo for
another 6 or 12 months. Recurrent VTE occurred in 1.3% of
patients receiving rivaroxaban compared to 7.1% of those on
placebo (HR 0.18; 95% CI 0.09–0.39; P,0.001), resulting
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in an 82% relative risk reduction (Table 2). The primary
safety endpoint of first major or clinically relevant nonmajor
bleeding occurred in 6.0% of those on rivaroxaban compared
to 1.2% in the placebo group (HR 5.19; 95% CI 2.3–11.7;
P,0.001) with the majority of the events being hematuria,
epistaxis, or rectal or skin bleeding. There was no significant
difference in major bleeding rates.
Similar to rivaroxaban, apixaban was also studied as
extended treatment of VTE in the AMPLIFY-EXT trial.21 This
randomized, double-blind study compared apixaban 5 mg BID,
2.5 mg BID, or placebo in 2,482 patients who completed 6–12
months of initial VTE treatment. Two-thirds of patients were
treated for a DVT and one-third for a PE, with majority (91%)
of events being unprovoked. After the 1-year study period, the
primary efficacy outcome of recurrent VTE or death from any
cause occurred in 4.2% of patients receiving apixaban 5 mg
(HR 0.36; 95% CI 0.25–0.53; P,0.001), 3.8% of patients
receiving apixaban 2.5 mg (HR 0.33; 95% CI 0.22–0.48;
P,0.001), and 11.6% of patients receiving placebo (Table 2).
Both doses of apixaban resulted in significantly less recurrent
VTE or deaths related to VTE compared to placebo (1.7%
[5 mg] versus 1.7% [2.5 mg] versus 8.8% [placebo]). There
was no significant difference in the primary safety endpoint
of major bleeding, and clinically relevant nonmajor bleeding
was increased in the apixaban 5 mg dose (4.2%; HR 1.82;
95% CI 1.05–3.18) compared to the 2.5 mg (3.0%; HR 1.29;
95% CI 0.72–2.33) and placebo (2.3%).

Oral factor-Xa inhibitors: potential
clinical advantages and their role
in VTE treatment
As the Phase III trials suggest, the new oral Xa inhibitors are
as effective as standard-of-care therapy and have similar, or
less in the case of apixaban and edoxaban, major bleeding
events compared with standard therapy. Nevertheless, providers should be cognizant of the details of the Phase III clinical
trials, as well as their clinical pharmacology and clinical
implications, when determining individualized patient selection of these agents for the treatment of a VTE event.
One advantage is the lack of the need for a heparin lead-in
phase, at least for rivaroxaban and apixaban. Even though all
of the new oral Xa inhibitors have a relatively quick onset of
action, reaching peak concentrations within approximately
3 hours, the edoxaban investigators opted to use a heparin
lead-in for all patients. Therefore, at this point, we do not
have data available to determine if the efficacy and safety of
starting edoxaban immediately at VTE presentation would
yield the same outcomes.
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Exclusion criteria for the Phase III trials were extensive
and warrant attention. Several patient populations were not
studied which may limit the generalizability of the trials.
There were very few patients above 75 years of age included
in these trials; in fact, in AMPLIFY-EXT, only 15% of
patients were older than 75 years of age.21 Patients with poor
renal function (CrCl ,30 mL/min) were excluded from the
trials. HOKUSAI-VTE did provide a dose reduction for those
patients with a CrCl of 30–50 mL/min, but the majority of
patients in the Phase III trials had good renal function. The
studies included a very small minority of patients that had
thrombophilic conditions or cancer. In the EINSTEIN-PE
trial, only about 5% of patients had a known thrombophilic condition.18 Additionally, very few patients had body
weights under 60 kg. The majority of patients were a mean
of 70–80 kg; therefore, minimal data exists in patients that
are severely under- or overweight. Caution is warranted
when extrapolating study results to these patient populations
(particularly as several of these comorbidities increase the
risk or are present in those with VTE) and when determining
individualized therapy regimens for any patients that fit such
populations or other exclusion criteria from the trials.
Another exclusion criterion from the trials was concomitant medications that would interact with the factor
Xa inhibitors. Although less drug interactions exist than
with warfarin, all three of the Xa inhibitors discussed are
CYP3A4 substrates, as well as P-gp substrates, which imply
they have the potential to interact with many medications
that are inhibitors or inducers of the enzymes. When given
concomitantly with an oral Xa inhibitor, strong CYP3A4 and
P-gp inhibitors, such as azole antifungals or HIV-protease
inhibitors, have the propensity to increase the anticoagulant’s
concentration. We have seen this interaction with rivaroxaban result in a more than twofold increase in rivaroxaban’s
mean AUC and Cmax.6,22 Additionally, coadministration
with oral ketoconazole once daily led to a twofold increase
in apixaban’s mean AUC and 1.6-fold increase in its mean
Cmax.23 Medications that moderately inhibit CYP3A4 or
P-gp are expected to increase the plasma concentrations of
the oral Xa inhibitors, but to a lesser extent. Therefore, it is
recommended that strong CYP3A4 or P-gp inhibitors not be
used in combination with the oral anti-Xa inhibitors to avoid
increased bleeding risk. Conversely, the combination of the
anticoagulants with strong CYP3A4 or P-gp inducers, such
as rifampicin, will lead to decreases in plasma concentrations
of the Xa inhibitors. In particular, when rifampicin was given
with rivaroxaban, it led to a 50% decrease in rivaroxaban’s
plasma concentration.6 Likewise, apixaban combined with
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rifampin led to a 54% decrease in apixaban’s mean AUC and
a 42% decrease in Cmax.7 Such decreases in exposure may
translate into decreased efficacy and therefore concomitant
administration should be avoided. In fact, patients that
were receiving strong CYP3A4 inhibitors or inducers were
excluded from the EINSTEIN trials, as well as the AMPLIFY
trials. Edoxaban undergoes CYP450 metabolism to a lesser
degree than rivaroxaban and apixaban; nevertheless, it does
interact with strong P-gp inhibitors. Based on pharmacokinetic studies, when edoxaban was administered with strong
P-gp inhibitors, quinidine, verapamil, and dronedarone, it
led to an increase in edoxaban’s maximum concentration
and exposure.24 Dose adjustments for such combinations can
be anticipated. In fact, the HOKUSAI-VTE study reduced
the dose if patients were on potent P-gp inhibitors, and the
Phase III study of edoxaban for stroke prevention in atrial
fibrillation, the ENGAGE AF-TIMI 48 trial, mandated a
protocol-directed 50% reduction of the edoxaban dose for
those patients receiving verapamil or quinidine.25
As with all anticoagulants, vigilance with concomitant use
of antiplatelets is warranted to avoid potentiation of antithrombotic effects and increased bleeding risks. All of the Phase III
studies discussed here excluded dual antiplatelet therapy, as well
as limited aspirin use to either doses 100 mg or 165 mg.
The EINSTEIN trial was the only trial that, although discouraged, did allow dual antiplatelet therapy of clopidogrel 75 mg
daily and aspirin 100 mg daily. Since minimal information
therefore exists with the oral Xa inhibitors in combination with
the various antiplatelet medications or high dose aspirin, close
monitoring is recommended to minimize bleeding risks.
Other advantages of the oral Xa inhibitors that are worth
considering when determining individualized patient treatment include the administration schedule and adherence.
Rivaroxaban is given twice daily for 3 weeks, then once daily;
apixaban is given twice daily with a dose change after 7 days;
whereas edoxaban is a once daily medication. Since the three
agents demonstrate linear, predictable therapeutic effects with
a fixed dose, none of the agents require routine monitoring
for anticoagulant effects, compared with warfarin’s INR
measurement.2 The absence of therapeutic monitoring could
be viewed as an advantage to improve patients quality of life
compared to frequent INR monitoring with warfarin, as well
as decreasing the healthcare provider’s workload. However,
it also results in decreased opportunities for patient education, as well as decreased ability to tailor patient-specific
therapy and to potentially detect issues early on, such as
nonadherence, bleeding, or thrombosis risks. Adherence
must be closely evaluated and discussed with the patient
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prior to oral anticoagulant agent selection, provided that the
oral Xa inhibitors have a short half- life and nonadherence
will quickly put the patient at increased risk of developing
recurrent thrombosis.
In the absence of routine monitoring, the therapeutic
effects of the oral Xa inhibitors at this point are not able to
be reversed. Their short half-lives, compared to warfarin’s,
do provide some assurance that the drug concentrations will
decline rapidly when therapy is discontinued in patients with
normal renal function. However, reversibility in emergent
situations, such as serious bleeding, trauma, or emergent
surgery, is unclear. Limited animal studies have suggested
that rivaroxaban can be reversed by infusion of recombinant
factor VIIa or prothrombin complex concentrates (PCC).26
In addition, a study completed in 12 human subjects demonstrated that 4-factor PCC reverses the effects of rivaroxaban,
determined by normalization of the prothrombin time and
endogenous thrombin potential immediately after the dose
was infused.27 There is also an ongoing Phase I trial investigating 4-factor PCC in patients treated with edoxaban.28
There is a factor Xa-specific antidote in development, andexanet alfa, which has shown favorable effects in Phase II trials.29
It is a recombinant, modified, specific factor Xa protein that
targets and binds to direct and indirect factor Xa inhibitors
in the blood, thereby inhibiting further binding to factor Xa,
and allowing restoration of hemostasis.29,30 More evidence
surrounding this antidote, and others, is forthcoming.

Conclusion
The oral factor Xa inhibitors, rivaroxaban, apixaban, and
edoxaban, show promise as effective alternatives to the standard therapy for VTE treatment. The clinical trial results show
noninferiority to standard therapy in acute treatment with
similar or less bleeding. In addition, they may have a role in
extended therapy to further prevent recurrent VTE events. As
no head-to-head trials exist, one must be cautious in comparing and interpreting differences in the Phase III clinical trials;
however, a recent, indirect comparison of the three agents
showed no statistically significant difference in the risk of
recurrent VTE or all-cause mortality between the agents, but
apixaban appeared to be associated with lower risk of bleeding compared to the other agents.31 Differences in the clinical
trials, including methodology and excluded patient populations, must be known when determining generalizability to
the real-world population. In addition, vigilance to different
pharmacological profiles and clinical implications is warranted when determining individualized patient care and
agent selection of these new anticoagulants.
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